Summary of Key Information:

Reporting Period (Quarter/Year): Quarter ended 30th June, 2026 (Q1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting and Unaudited Standalone Financial Results under Regulation 30 of SEBI (LODR), 2015

Audit Opinion:

Clean. The Limited Review Report by CA Miral Bipinbhai Mehta, Partner of Sarupria Somani & Associates, contained no modifications or qualifications.

Auditor’s Comment: Nothing has come to our attention that causes us to believe that the accompanying statement... contains any material misstatement.

Key Financial Highlights [Rs. In Lakhs]

Standalone Results:

Quarter Ended 30-06-2026 (Unaudited) vs. 30-06-2025 (Unaudited):

  • Revenue from Operations: ₹3,128.05 (vs. ₹2,604.64 prior year) - Increase of 20.1% YoY
  • Total Income: ₹3,221.58 (vs. ₹2,788.31 prior year)
  • EBITDA: Not Specified
  • Net Profit: ₹471.27 (vs. ₹332.80 prior year) - Increase of 41.6% YoY
  • EPS (Basic & Diluted): ₹3.83 (vs. ₹2.70 prior year)
  • Other Equity: Reserves & Surplus stood at ₹10,439.27
  • Cash and Cash Equivalents: Not Specified
  • Debt: Finance costs were ₹2.14, indicating minimal outstanding debt.

Quarter Ended 30-06-2026 (Unaudited) vs. 31-03-2026 (Audited):

  • Revenue from Operations: ₹3,128.05 (vs. ₹1,961.08 previous quarter)
  • Net Profit: ₹471.27 (vs. ₹85.36 previous quarter)
  • EPS: ₹3.83 (vs. ₹0.69 previous quarter)

Consolidated Results:

Not Applicable. The company does not have any subsidiary, associates, or joint ventures; therefore, only standalone results are prepared.

Segment-wise Performance:

The company is primarily engaged in the manufacturing of API (Active Pharmaceutical Ingredient), which constitutes a single business segment. There are no separate reportable segments.

Corporate Actions:

  • Dividend: Not Specified
  • Share Split/Bonus/Buyback: Not Specified
  • Capital Raising: The board approved availing forward booking banking facilities from ICICI Bank. Specific size not disclosed.

Other Significant Information:

  • Banking Facilities: Board approved a resolution to avail forward booking facilities from ICICI Bank. Mr. Falgun V. Savani and Mr. Jignesh V. Savani were authorized to execute necessary documents.
  • Portfolio Management: Board approved the appointment of NEO Alternative Asset Managers Private Limited (SEBI Registration No.: INP000007641) as a Portfolio Manager and to open a demat account with them.
  • Vehicle Sale & Purchase:
  • Approved the sale of an existing motor vehicle for approximately ₹3.60 Lakh.
  • Approved the purchase of two new vehicles:
  • 1 Toyota Fortuner Legender (for Mr. Jignesh V. Savani): Ex-showroom price of ₹42.92 Lakh plus taxes and charges.
  • 1 Mahindra XUV 9E (for Mr. Falgun V. Savani): Ex-showroom price of ₹29.43 Lakh plus taxes and charges.
  • Entities in Consolidation: None. The company has no subsidiaries, associates, or joint ventures.
  • Exceptional Items: None.
  • Change in Accounting Policy: None reported.
  • Guidance/Outlook: Not Specified.